Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for ACAD

Stock Name	ACADIA Pharmaceuticals Inc
Ticker	ACAD(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US0042251084
LEI	529900O3044NO0PEA039

Show aggregate ACAD holdings

News associated with ACAD

Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $28.88: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nineteen brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has […] - 2025-09-12 02:48:53
UBS Group Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price target increased by investment analysts at UBS Group from $36.00 to $39.00 in a report issued on Tuesday, MarketBeat Ratings reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. UBS Group’s price objective indicates a potential upside of 63.87% from the […] - 2025-09-11 02:49:04
Deutsche Bank AG Has $12.63 Million Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Deutsche Bank AG trimmed its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 760,594 shares of the biopharmaceutical company’s stock after selling 281,853 shares during the period. Deutsche Bank AG owned […] - 2025-08-15 05:17:01
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Holdings Boosted by Zurcher Kantonalbank Zurich Cantonalbank: Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.2% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,256 shares of the biopharmaceutical company’s stock after purchasing an additional 3,389 shares during the period. […] - 2025-08-08 04:56:48
Mackenzie Financial Corp Grows Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Mackenzie Financial Corp boosted its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 58,379 shares of the biopharmaceutical company’s stock after buying an additional 7,314 shares during the period. Mackenzie […] - 2025-08-06 04:36:58
Envestnet Asset Management Inc. Buys 36,003 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Envestnet Asset Management Inc. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 33.8% during the 1st quarter, HoldingsChannel.com reports. The fund owned 142,667 shares of the biopharmaceutical company’s stock after acquiring an additional 36,003 shares during the period. Envestnet Asset Management Inc.’s holdings in ACADIA Pharmaceuticals were worth $2,370,000 […] - 2025-07-29 04:08:59
Analysts Predict 15% Upside For The Holdings of IJR: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-28 10:46:16
Cerity Partners LLC Sells 3,872 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Cerity Partners LLC trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 18.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 16,587 shares of the biopharmaceutical company’s stock after selling 3,872 shares during the period. Cerity Partners LLC’s holdings in ACADIA Pharmaceuticals were […] - 2025-07-28 04:46:48
Xponance Inc. Acquires 1,434 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Xponance Inc. boosted its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 14.1% in the 1st quarter, Holdings Channel.com reports. The firm owned 11,585 shares of the biopharmaceutical company’s stock after purchasing an additional 1,434 shares during the quarter. Xponance Inc.’s holdings in ACADIA Pharmaceuticals were worth $192,000 as of its […] - 2025-07-21 06:12:11
Bank of New York Mellon Corp Boosts Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Bank of New York Mellon Corp boosted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 96.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 804,390 shares of the biopharmaceutical company’s stock after acquiring an additional 394,640 shares during […] - 2025-07-21 04:30:53
New York State Teachers Retirement System Grows Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): New York State Teachers Retirement System grew its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 547.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,625 shares of the biopharmaceutical company’s stock after acquiring an additional 28,435 shares during […] - 2025-07-11 05:34:49
72,125 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Acquired by Illinois Municipal Retirement Fund: Illinois Municipal Retirement Fund bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 72,125 shares of the biopharmaceutical company’s stock, valued at approximately $1,198,000. Other […] - 2025-07-02 05:28:55
SG Americas Securities LLC Sells 2,465,581 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): SG Americas Securities LLC decreased its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 99.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 18,150 shares of the biopharmaceutical company’s stock after selling 2,465,581 shares during the quarter. SG Americas […] - 2025-06-27 04:18:48
State of Alaska Department of Revenue Invests $1.13 Million in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): State of Alaska Department of Revenue purchased a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the 1st quarter, HoldingsChannel.com reports. The firm purchased 68,225 shares of the biopharmaceutical company’s stock, valued at approximately $1,133,000. Several other hedge funds and other institutional investors have also recently modified their holdings of ACAD. Principal […] - 2025-06-26 04:43:03
Royal Bank Of Canada Forecasts Strong Price Appreciation for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price raised by stock analysts at Royal Bank Of Canada from $26.00 to $38.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price objective indicates a potential upside of […] - 2025-06-25 02:36:49
KMDA vs. ACAD: Which Stock Is the Better Value Option?: KMDA vs. ACAD: Which Stock Is the Better Value Option? - 2025-06-18 12:40:06
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Director Sells $314,633.88 in Stock: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) Director Laura Brege sold 14,446 shares of the firm’s stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the sale, the director now directly owns 15,095 […] - 2025-06-09 05:36:49
ProShare Advisors LLC Has $763,000 Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): ProShare Advisors LLC increased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 28.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 41,580 shares of the biopharmaceutical company’s stock after purchasing an additional 9,164 shares during the period. ProShare Advisors LLC’s holdings in ACADIA Pharmaceuticals were worth $763,000 […] - 2025-05-25 06:03:26
Bank of America Corp DE Grows Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Bank of America Corp DE raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 41.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 680,853 shares of the biopharmaceutical company’s stock after acquiring an additional 199,504 shares during the quarter. Bank of America Corp DE’s holdings in ACADIA Pharmaceuticals were worth […] - 2025-05-23 05:19:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $24.00: ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price lifted by Morgan Stanley from $20.00 to $24.00 in a research report sent to investors on Tuesday morning,Benzinga reports. Morgan Stanley currently has an equal weight rating on the biopharmaceutical company’s stock. A number of other research analysts have also issued reports on ACAD. Wall […] - 2025-05-23 02:52:57
ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $35.00 at Deutsche Bank Aktiengesellschaft: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its price objective upped by research analysts at Deutsche Bank Aktiengesellschaft from $20.00 to $35.00 in a research note issued on Wednesday, MarketBeat reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective points to a potential upside of […] - 2025-05-23 02:52:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Trading Up 3.5% Following Analyst Upgrade: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was up 3.5% during mid-day trading on Wednesday after Wall Street Zen upgraded the stock from a hold rating to a buy rating. The stock traded as high as $22.75 and last traded at $22.44. Approximately 376,453 shares traded hands during mid-day trading, a decline of 84% […] - 2025-05-23 02:03:06
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at StockNews.com: StockNews.com upgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a hold rating to a buy rating in a report issued on Wednesday. Several other brokerages have also commented on ACAD. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of ACADIA Pharmaceuticals in a research report […] - 2025-05-22 04:50:50
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $32.00 Price Target at HC Wainwright: ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) had its target price increased by equities researchers at HC Wainwright from $27.00 to $32.00 in a research report issued on Monday, MarketBeat Ratings reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s target price would indicate a potential upside of 47.53% […] - 2025-05-21 02:42:45
Robert W. Baird Raises ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $31.00: ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target raised by Robert W. Baird from $28.00 to $31.00 in a report issued on Monday,Benzinga reports. The firm currently has an outperform rating on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on ACAD. BMO Capital Markets increased their […] - 2025-05-20 02:36:58
Northern Trust Corp Has $22.61 Million Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Northern Trust Corp increased its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 9.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,232,366 shares of the biopharmaceutical company’s stock after buying an additional 106,236 shares during the period. Northern Trust Corp owned 0.74% […] - 2025-05-13 06:14:59
Traders Purchase Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD): ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw unusually large options trading activity on Thursday. Stock traders purchased 2,626 call options on the company. This is an increase of 146% compared to the average daily volume of 1,068 call options. Insider Buying and Selling In other news, Director Elizabeth A. Garofalo sold 4,919 shares […] - 2025-05-09 02:38:58
Envestnet Asset Management Inc. Decreases Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Envestnet Asset Management Inc. lessened its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 10.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 106,664 shares of the biopharmaceutical company’s stock after selling 12,037 shares during the quarter. Envestnet Asset […] - 2025-04-28 04:38:49
Legal & General Group Plc Sells 2,348 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Legal & General Group Plc cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 133,042 shares of the biopharmaceutical company’s stock after selling 2,348 shares during the quarter. Legal & General […] - 2025-04-25 05:16:54
Cerity Partners LLC Acquires 6,173 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD): Cerity Partners LLC increased its holdings in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 43.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,459 shares of the biopharmaceutical company’s stock after acquiring an additional 6,173 shares during the quarter. […] - 2025-04-24 04:52:50

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ACAD holdings

Date	Number of ACAD Shares Held	Base Market Value of ACAD Shares	Local Market Value of ACAD Shares	Change in ACAD Shares Held	Change in ACAD Base Value	Current Price per ACAD Share Held	Previous Price per ACAD Share Held
2025-11-12 (Wednesday)	12,598	USD 303,990	USD 303,990	-41	USD 4,193	USD 24.13	USD 23.72
2025-11-11 (Tuesday)	12,639	USD 299,797	USD 299,797	0	USD 19,211	USD 23.72	USD 22.2
2025-11-10 (Monday)	12,639	USD 280,586	USD 280,586	0	USD -4,676	USD 22.2	USD 22.57
2025-11-07 (Friday)	12,639	USD 285,262	USD 285,262	0	USD 11,628	USD 22.57	USD 21.65
2025-11-06 (Thursday)	12,639	USD 273,634	USD 273,634	-41	USD -9,510	USD 21.65	USD 22.33
2025-11-05 (Wednesday)	12,680	USD 283,144	USD 283,144	-410	USD -2,873	USD 22.33	USD 21.85
2025-11-04 (Tuesday)	13,090	USD 286,017	USD 286,017	-82	USD -8,641	USD 21.85	USD 22.37
2025-11-03 (Monday)	13,172	USD 294,658	USD 294,658	-82	USD -6,208	USD 22.37	USD 22.7
2025-10-31 (Friday)	13,254	USD 300,866	USD 300,866	0	USD -530	USD 22.7	USD 22.74
2025-10-30 (Thursday)	13,254	USD 301,396	USD 301,396	0	USD 2,783	USD 22.74	USD 22.53
2025-10-29 (Wednesday)	13,254	USD 298,613	USD 298,613	0	USD -1,192	USD 22.53	USD 22.62
2025-10-28 (Tuesday)	13,254	USD 299,805	USD 299,805	123	USD -2,077	USD 22.62	USD 22.99
2025-10-27 (Monday)	13,131	USD 301,882	USD 301,882	0	USD 12,737	USD 22.99	USD 22.02

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ACAD by Blackrock for IE00B3VWM098

Show aggregate share trades of ACAD

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-12 SELL -41 24.390 23.380 23.481 USD -963 19.04 Loss of -182 on sale
2025-11-06 SELL -41 23.580 20.640 20.934 USD -858 18.97 Loss of -81 on sale
2025-11-05 SELL -410 22.520 21.690 21.773 USD -8,927 18.95 Loss of -1,158 on sale
2025-11-04 SELL -82 22.200 21.720 21.768 USD -1,785 18.93 Loss of -232 on sale
2025-11-03 SELL -82 22.770 21.880 21.969 USD -1,801 18.92 Loss of -250 on sale
2025-10-28 BUY 123 22.620 23.050 23.007 USD 2,830 18.84
2025-10-24 SELL -41 22.020 22.190 22.173 USD -909 18.80 Loss of -138 on sale
2025-10-15 BUY 246 21.740 21.920 21.902 USD 5,388 18.70
2025-10-02 BUY 41 21.380 21.490 21.479 USD 881 18.67
2025-09-30 BUY 82 21.340 21.480 21.466 USD 1,760 18.64
2025-09-11 BUY 164 24.200 24.460 24.434 USD 4,007 18.53
2025-08-21 SELL -41 24.790 25.070 25.042 USD -1,027 18.49 Loss of -269 on sale
2025-07-31 BUY 123 23.830 24.060 24.037 USD 2,957 18.42
2025-06-30 SELL -82 21.570 22.260 22.191 USD -1,820 17.95 Loss of -348 on sale
2025-06-25 SELL -41 22.500 23.040 22.986 USD -942 17.86 Loss of -210 on sale
2025-06-20 SELL -82 22.710 23.240 23.187 USD -1,901 17.76 Loss of -445 on sale
2025-05-23 BUY 41 21.980 22.030 22.025 USD 903 17.05
2025-05-19 SELL -41 21.990 22.450 22.404 USD -919 16.89 Loss of -226 on sale
2025-05-15 SELL -123 17.600 17.640 17.636 USD -2,169 16.83 Loss of -99 on sale
2025-05-12 SELL -41 17.520 18.090 18.033 USD -739 16.82 Loss of -50 on sale
2025-05-09 SELL -41 17.440 17.620 17.602 USD -722 16.82 Loss of -32 on sale
2025-04-30 SELL -41 14.600 14.650 14.645 USD -600 16.93 Profit of 94 on sale
2025-04-24 SELL -82 14.830 14.850 14.848 USD -1,218 17.02 Profit of 178 on sale
2025-04-17 SELL -41 14.730 14.750 14.748 USD -605 17.15 Profit of 99 on sale
2025-04-15 SELL -123 14.990 15.180 15.161 USD -1,865 17.20 Profit of 251 on sale
2025-04-14 SELL -123 14.860 15.000 14.986 USD -1,843 17.23 Profit of 276 on sale
2025-04-09 SELL -164 14.960 15.190 15.167 USD -2,487 17.32 Profit of 353 on sale
2025-04-07 SELL -287 14.610 15.700 15.591 USD -4,475 17.39 Profit of 516 on sale
2025-04-04 SELL -410 15.380 15.970 15.911 USD -6,524 17.41 Profit of 615 on sale
2025-03-31 BUY 41 16.610 16.880 16.853 USD 691 17.44
2025-03-19 SELL -82 17.290 17.600 17.569 USD -1,441 17.48 Loss of -7 on sale
2025-03-14 SELL -246 17.500 17.700 17.680 USD -4,349 17.49 Loss of -48 on sale
2025-03-13 SELL -82 16.780 16.910 16.897 USD -1,386 17.50 Profit of 49 on sale
2025-03-12 SELL -1,394 16.770 17.400 17.337 USD -24,168 17.51 Profit of 236 on sale
2025-03-07 SELL -82 17.560 17.860 17.830 USD -1,462 17.51 Loss of -26 on sale
2025-03-06 SELL -123 17.610 18.150 18.096 USD -2,226 17.51 Loss of -72 on sale
2025-03-03 SELL -41 18.160 19.690 19.537 USD -801 17.48 Loss of -84 on sale
2025-02-28 SELL -246 19.600 19.620 19.618 USD -4,826 17.45 Loss of -534 on sale
2025-02-26 SELL -41 19.000 19.650 19.585 USD -803 17.39 Loss of -90 on sale
2025-02-25 SELL -123 19.010 19.720 19.649 USD -2,417 17.36 Loss of -281 on sale
2025-02-18 BUY 205 19.740 20.290 20.235 USD 4,148 17.09
2025-02-13 BUY 41 19.770 19.830 19.824 USD 813 16.92
2025-02-12 BUY 41 19.100 19.110 19.109 USD 783 16.87
2025-02-11 BUY 123 18.490 18.700 18.679 USD 2,298 16.84
2025-02-06 BUY 369 19.130 19.700 19.643 USD 7,248 16.70
2025-01-27 BUY 41 18.270 19.050 18.972 USD 778 16.28
2024-12-30 BUY 205 16.690 16.810 16.798 USD 3,444 16.04
2024-12-06 BUY 164 17.280 17.360 17.352 USD 2,846 15.82
2024-12-05 BUY 41 16.710 17.210 17.160 USD 704 15.79
2024-12-04 BUY 205 17.170 17.260 17.251 USD 3,536 15.75
2024-11-29 BUY 205 16.320 16.410 16.401 USD 3,362 15.67
2024-11-27 BUY 164 16.290 16.480 16.461 USD 2,700 15.61
2024-11-26 BUY 41 16.210 16.470 16.444 USD 674 15.58
2024-11-21 BUY 205 16.180 16.420 16.396 USD 3,361 15.46
2024-11-20 BUY 123 16.270 16.390 16.378 USD 2,014 15.42
2024-11-18 BUY 492 17.030 17.170 17.156 USD 8,441 15.27
2024-11-12 BUY 328 17.930 18.400 18.353 USD 6,020 15.09
2024-11-08 BUY 205 17.660 17.970 17.939 USD 3,677 14.90
2024-11-07 BUY 615 17.200 17.490 17.461 USD 10,739 14.73
2024-11-06 BUY 82 15.790 15.850 15.844 USD 1,299 14.64
2024-10-31 BUY 41 14.590 14.770 14.752 USD 605 14.58
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-12	SELL	-41	24.390	23.380	23.481	USD -963	19.04 Loss of -182 on sale
2025-11-06	SELL	-41	23.580	20.640	20.934	USD -858	18.97 Loss of -81 on sale
2025-11-05	SELL	-410	22.520	21.690	21.773	USD -8,927	18.95 Loss of -1,158 on sale
2025-11-04	SELL	-82	22.200	21.720	21.768	USD -1,785	18.93 Loss of -232 on sale
2025-11-03	SELL	-82	22.770	21.880	21.969	USD -1,801	18.92 Loss of -250 on sale
2025-10-28	BUY	123	22.620	23.050	23.007	USD 2,830	18.84
2025-10-24	SELL	-41	22.020	22.190	22.173	USD -909	18.80 Loss of -138 on sale
2025-10-15	BUY	246	21.740	21.920	21.902	USD 5,388	18.70
2025-10-02	BUY	41	21.380	21.490	21.479	USD 881	18.67
2025-09-30	BUY	82	21.340	21.480	21.466	USD 1,760	18.64
2025-09-11	BUY	164	24.200	24.460	24.434	USD 4,007	18.53
2025-08-21	SELL	-41	24.790	25.070	25.042	USD -1,027	18.49 Loss of -269 on sale
2025-07-31	BUY	123	23.830	24.060	24.037	USD 2,957	18.42
2025-06-30	SELL	-82	21.570	22.260	22.191	USD -1,820	17.95 Loss of -348 on sale
2025-06-25	SELL	-41	22.500	23.040	22.986	USD -942	17.86 Loss of -210 on sale
2025-06-20	SELL	-82	22.710	23.240	23.187	USD -1,901	17.76 Loss of -445 on sale
2025-05-23	BUY	41	21.980	22.030	22.025	USD 903	17.05
2025-05-19	SELL	-41	21.990	22.450	22.404	USD -919	16.89 Loss of -226 on sale
2025-05-15	SELL	-123	17.600	17.640	17.636	USD -2,169	16.83 Loss of -99 on sale
2025-05-12	SELL	-41	17.520	18.090	18.033	USD -739	16.82 Loss of -50 on sale
2025-05-09	SELL	-41	17.440	17.620	17.602	USD -722	16.82 Loss of -32 on sale
2025-04-30	SELL	-41	14.600	14.650	14.645	USD -600	16.93 Profit of 94 on sale
2025-04-24	SELL	-82	14.830	14.850	14.848	USD -1,218	17.02 Profit of 178 on sale
2025-04-17	SELL	-41	14.730	14.750	14.748	USD -605	17.15 Profit of 99 on sale
2025-04-15	SELL	-123	14.990	15.180	15.161	USD -1,865	17.20 Profit of 251 on sale
2025-04-14	SELL	-123	14.860	15.000	14.986	USD -1,843	17.23 Profit of 276 on sale
2025-04-09	SELL	-164	14.960	15.190	15.167	USD -2,487	17.32 Profit of 353 on sale
2025-04-07	SELL	-287	14.610	15.700	15.591	USD -4,475	17.39 Profit of 516 on sale
2025-04-04	SELL	-410	15.380	15.970	15.911	USD -6,524	17.41 Profit of 615 on sale
2025-03-31	BUY	41	16.610	16.880	16.853	USD 691	17.44
2025-03-19	SELL	-82	17.290	17.600	17.569	USD -1,441	17.48 Loss of -7 on sale
2025-03-14	SELL	-246	17.500	17.700	17.680	USD -4,349	17.49 Loss of -48 on sale
2025-03-13	SELL	-82	16.780	16.910	16.897	USD -1,386	17.50 Profit of 49 on sale
2025-03-12	SELL	-1,394	16.770	17.400	17.337	USD -24,168	17.51 Profit of 236 on sale
2025-03-07	SELL	-82	17.560	17.860	17.830	USD -1,462	17.51 Loss of -26 on sale
2025-03-06	SELL	-123	17.610	18.150	18.096	USD -2,226	17.51 Loss of -72 on sale
2025-03-03	SELL	-41	18.160	19.690	19.537	USD -801	17.48 Loss of -84 on sale
2025-02-28	SELL	-246	19.600	19.620	19.618	USD -4,826	17.45 Loss of -534 on sale
2025-02-26	SELL	-41	19.000	19.650	19.585	USD -803	17.39 Loss of -90 on sale
2025-02-25	SELL	-123	19.010	19.720	19.649	USD -2,417	17.36 Loss of -281 on sale
2025-02-18	BUY	205	19.740	20.290	20.235	USD 4,148	17.09
2025-02-13	BUY	41	19.770	19.830	19.824	USD 813	16.92
2025-02-12	BUY	41	19.100	19.110	19.109	USD 783	16.87
2025-02-11	BUY	123	18.490	18.700	18.679	USD 2,298	16.84
2025-02-06	BUY	369	19.130	19.700	19.643	USD 7,248	16.70
2025-01-27	BUY	41	18.270	19.050	18.972	USD 778	16.28
2024-12-30	BUY	205	16.690	16.810	16.798	USD 3,444	16.04
2024-12-06	BUY	164	17.280	17.360	17.352	USD 2,846	15.82
2024-12-05	BUY	41	16.710	17.210	17.160	USD 704	15.79
2024-12-04	BUY	205	17.170	17.260	17.251	USD 3,536	15.75
2024-11-29	BUY	205	16.320	16.410	16.401	USD 3,362	15.67
2024-11-27	BUY	164	16.290	16.480	16.461	USD 2,700	15.61
2024-11-26	BUY	41	16.210	16.470	16.444	USD 674	15.58
2024-11-21	BUY	205	16.180	16.420	16.396	USD 3,361	15.46
2024-11-20	BUY	123	16.270	16.390	16.378	USD 2,014	15.42
2024-11-18	BUY	492	17.030	17.170	17.156	USD 8,441	15.27
2024-11-12	BUY	328	17.930	18.400	18.353	USD 6,020	15.09
2024-11-08	BUY	205	17.660	17.970	17.939	USD 3,677	14.90
2024-11-07	BUY	615	17.200	17.490	17.461	USD 10,739	14.73
2024-11-06	BUY	82	15.790	15.850	15.844	USD 1,299	14.64
2024-10-31	BUY	41	14.590	14.770	14.752	USD 605	14.58

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ACAD

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	177,131	200	310,627	57.0%
2025-09-18	231,742	428	554,082	41.8%
2025-09-17	277,075	374	461,418	60.0%
2025-09-16	292,134	2,622	560,920	52.1%
2025-09-15	608,488	6,416	1,142,651	53.3%
2025-09-12	234,478	0	584,492	40.1%
2025-09-11	237,345	0	578,233	41.0%
2025-09-10	406,173	918	959,743	42.3%
2025-09-09	416,192	8,875	1,219,148	34.1%
2025-09-08	275,369	917	543,613	50.7%
2025-09-05	203,992	4,543	403,138	50.6%
2025-09-04	357,546	11,463	821,948	43.5%
2025-09-03	165,767	0	471,567	35.2%
2025-09-02	379,278	123,302	944,994	40.1%
2025-08-29	178,641	647	380,604	46.9%
2025-08-28	347,632	42,128	704,639	49.3%
2025-08-27	735,312	73,271	1,108,402	66.3%
2025-08-26	383,113	1,531	782,128	49.0%
2025-08-25	415,483	632	763,460	54.4%
2025-08-22	927,948	813	1,757,013	52.8%
2025-08-21	224,011	0	400,364	56.0%
2025-08-20	121,997	202	279,171	43.7%
2025-08-19	231,080	0	456,081	50.7%
2025-08-18	679,222	196	963,982	70.5%
2025-08-15	641,994	5,137	984,489	65.2%
2025-08-14	332,247	0	569,267	58.4%
2025-08-13	267,703	1,852	555,599	48.2%
2025-08-12	505,509	6,990	849,125	59.5%
2025-08-11	257,130	2,117	493,093	52.1%
2025-08-08	313,380	73	531,753	58.9%
2025-08-07	381,332	3,323	621,473	61.4%
2025-08-06	256,267	142	516,141	49.7%
2025-08-05	314,036	470	596,278	52.7%
2025-08-04	265,143	235	549,947	48.2%
2025-08-01	242,661	100	835,083	29.1%
2025-07-31	356,257	876	685,250	52.0%
2025-07-30	515,390	335	843,656	61.1%
2025-07-29	280,257	6,520	405,607	69.1%
2025-07-28	328,072	654	464,165	70.7%
2025-07-25	169,818	0	295,055	57.6%
2025-07-24	304,773	1,105	461,020	66.1%
2025-07-23	228,907	1,204	403,501	56.7%
2025-07-22	159,551	1,542	259,145	61.6%
2025-07-21	214,521	1	304,308	70.5%
2025-07-18	165,636	2,788	227,873	72.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE